<SEC-DOCUMENT>0001558370-17-001671.txt : 20170313
<SEC-HEADER>0001558370-17-001671.hdr.sgml : 20170313
<ACCEPTANCE-DATETIME>20170313160020
ACCESSION NUMBER:		0001558370-17-001671
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170309
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170313
DATE AS OF CHANGE:		20170313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		17685199

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>glyc_currentfolio8k.htm
<DESCRIPTION>8-K
<TEXT>
<!--HTML document created with Merrill Bridge  6.4.50.0-->
<!--Created on: 3/13/2017 1:54:44 PM-->
<html>
	<head>
		<title>
			glyc_Current Folio 8k
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;border-top:3pt double #000000 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<font style="display:inline;font-size:18pt;">UNITED STATES</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<font style="display:inline;font-weight:bold;font-size:18pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Washington, DC 20549</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1.2pt;color:black;background-color:black;" align="center"></hr></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<font style="display:inline;font-weight:bold;font-size:18pt;">FORM 8&#8209;K</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;">CURRENT REPORT</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;">Pursuant to Section 13 or 15(d) of</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;">The Securities Exchange Act of 1934</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Date of Report (Date of earliest event reported): March 9, 2017</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1.2pt;color:black;background-color:black;" align="center"></hr></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<font style="display:inline;font-weight:bold;font-size:18pt;">GlycoMimetics, Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(Exact name of registrant as specified in its charter)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:29.44%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.74%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.78%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.54%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:29.44%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Delaware</font></p>
				</td>
				<td valign="bottom" style="width:03.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.78%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;text-decoration:underline;">001-36177</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.54%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;text-decoration:underline;">06-1686563</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:29.44%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">(State or other jurisdiction of&nbsp;incorporation)</font></p>
				</td>
				<td valign="bottom" style="width:03.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.78%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">(Commission File Number)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">(IRS Employer<br />Identification No.)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">9708 Medical Center Drive</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Rockville, MD 20850&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(Address of principal executive offices, including zip code)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">(240) 243-1201</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(Registrant&#x2019;s telephone number, including area code)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">N/A</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(Former name or former address, if changed since last report)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:5pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font>
		</p>
		<p style="margin:5pt 0pt 5pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">[&nbsp;&nbsp;] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font>
		</p>
		<p style="margin:5pt 0pt 5pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">[&nbsp;&nbsp;] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font>
		</p>
		<p style="margin:5pt 0pt 5pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.25pt;text-indent: -14.25pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font>
		</p>
		<p style="margin:0pt;border-bottom:3pt double #000000 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:5pt 0pt 12pt 45pt;text-indent: -45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Item 5.02&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;">On March 9, 2017, the Board of Directors (the &#x201C;</font><font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Board</font><font style="display:inline;font-size:10pt;">&#x201D;) of GlycoMimetics, Inc. (the &#x201C;</font><font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Company</font><font style="display:inline;font-size:10pt;">&#x201D;) appointed Scott Koenig, M.D., Ph.D.&nbsp;to serve as a director of the Company and a member of the Nominating and Corporate Governance Committee of the Board.&nbsp;&nbsp;Dr. Koenig will serve as a Class II director whose term will expire at the 2019 Annual Meeting of Stockholders.&nbsp; There is no arrangement or understanding between Dr. Koenig and any other person pursuant to which he was selected as a director of the Company, and there is no family relationship between Dr. Koenig and any of the Company&#x2019;s other directors or executive officers.&nbsp;&nbsp;The Company is not aware of any transaction involving Dr. Koenig requiring disclosure under Item 404(a) of Regulation S-K. Additional information about Dr. Koenig is set forth below.</font>
		</p>
		<p style="margin:12pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;"></font><font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Scott Koenig, M.D., Ph.D.</font><font style="display:inline;font-size:10pt;">, age 64, has served as a member of our Board since March 2017.&nbsp; Dr. Koenig has served as President and Chief Executive Officer and a director of Macrogenics, Inc., a public company (NASDAQ: MGNX) since September 2001 and was one of its co-founders. Prior to joining Macrogenics, Dr. Koenig served as Senior Vice President of Research at MedImmune, Inc., where he participated in the selection and maturation of their product pipeline. From 1984 to 1990, he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Dr. Koenig currently serves as Chairman of the Board of Directors of Applied Genetic Technologies Corporation, a public company (NASDAQ: AGTC), and the Children&#x2019;s Research Institute. Additionally, Dr. Koenig serves on the Board of Directors of Children&#x2019;s National Medical Center, the International Biomedical Research Alliance, and the Biotechnology Innovation Organization.</font>
		</p>
		<p style="margin:12pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;">In accordance with the Company&#x2019;s compensation policy for non-employee directors, upon his appointment as a director, Dr. Koenig was granted a nonqualified stock option to purchase 22,000 shares of the Company&#x2019;s common stock at an exercise price of $6.59, the closing price of the Company&#x2019;s common stock on the date of grant.&nbsp;&nbsp;This option will vest and become exercisable in three equal installments on the first, second and third anniversaries of the date of grant subject to Dr. Koenig&#x2019;s Continuous Service (as defined in the Company&#x2019;s 2013 Equity Incentive Plan) through such vesting periods.&nbsp;&nbsp;Additionally, Dr. Koenig will be entitled to receive a $35,000 annual retainer for his service as director and a $4,000 annual retainer for his service on the Nominating and Corporate Governance Committee.&nbsp;&nbsp;At each annual stockholder meeting following which Dr. Koenig&#x2019;s term as a director continues, Dr. Koenig will be entitled to receive an additional nonqualified stock option to purchase 11,000 shares of the Company&#x2019;s common stock, which option will vest and become exercisable over a one-year period following the date of grant.&nbsp;&nbsp;Dr. Koenig has also entered into the Company&#x2019;s standard form of indemnification agreement.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;font-style:italic;font-size:10pt;">Resignation of John J. Baldwin, Ph.D. as a Member of the Board of Directors</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;">On March 9, 2017, John J. Baldwin Ph.D., notified the Board of his intention to resign as a director of the Company at the conclusion of the Company&#x2019;s 2017 Annual Meeting of Stockholders to be held on May 25, 2017.&nbsp;&nbsp;Dr. Baldwin will remain a Member of the Nominating and Corporate Governance Committee and Audit Committee of the Board until the conclusion of the 2017 Annual Meeting of Stockholders.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;font-size:10pt;">&#x201C;On behalf of the Board and the entire GlycoMimetics team, we wish to thank Jack for his service over the years and wish him well in his future endeavors. Jack was a founding board member of GlycoMimetics and his guidance has been invaluable to the Company,&#x201D; said Rachel K. King, Chief Executive Officer of the Company.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Regulation FD Disclosure.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">On March 13, 2017, the Company issued a press release announcing Dr. Koenig&#x2019;s appointment to the Board.&nbsp; A copy of this press release is furnished herewith as Exhibit&nbsp;99.1 to this Current Report.</font><font style="display:inline;color:#000000;font-size:10pt;"> The information contained in the press release furnished as Exhibit 99.1 shall not be deemed &#x201C;filed&#x201D; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201C;</font><font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Exchange Act</font><font style="display:inline;color:#000000;font-size:10pt;">&#x201D;), and is not incorporated by reference into any of the Company&#x2019;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Item 9.01 Exhibits.</font><font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">(d)&nbsp;Exhibits</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:09.74%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Exhibit</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:88.94%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.74%;border-bottom:1pt solid #000000 ;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Number</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:88.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Exhibit&nbsp;Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.74%;border-top:1pt solid #000000 ;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:11.25pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99.1
				</td>
				<td valign="bottom" style="width:01.34%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:88.94%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:5pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Press Release dated March 13, 2017, &#x201C;GlycoMimetics Appoints Scott Koenig of Macrogenics to Board of Directors.&#x201D;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">SIGNATURES</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:37.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:41.08%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">GLYCOMIMETICS, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.08%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:55.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.36%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.08%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">/s/ Brian M. Hahn</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Date:&nbsp;&nbsp;March 13, 2017</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.08%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Brian M. Hahn</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:41.08%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Chief Financial Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">EXHIBIT INDEX</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:10.10%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Exhibit</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:88.52%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.10%;border-bottom:1pt solid #000000 ;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Number</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:88.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Exhibit&nbsp;Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.10%;border-top:1pt solid #000000 ;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:11.25pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99.1
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:88.52%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:5pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Press Release dated March 13, 2017, &#x201C;GlycoMimetics Appoints Scott Koenig of Macrogenics to Board of Directors.&#x201D;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>glyc_ex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Merrill Bridge  6.4.50.0-->
<!--Created on: 3/13/2017 1:54:42 PM-->
<html>
	<head>
		<title>
			glyc_Ex99_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;">Exhibit 99.1</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;"><img src="glycex991001.jpg" style="width: 3.76in; height: 0.82in" alt="Picture 1"></font>
		</p>
		<p style="margin:0pt;line-height:100%;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Courier New;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Courier New;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;text-transform:none;">GLYCOMIMETICS APPOINTS SCOTT KOENIG OF MACROGENICS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Courier New;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;text-transform:none;">TO BOARD OF DIRECTORS</font>
		</p>
		<p style="margin:0pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Courier New;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:normal;font-style:italic;text-transform:none;">Two Long-Time Board Members to Step Down </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;border-top:1pt none #D9D9D9 ;text-align:center;font-family:Courier New;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:normal;font-style:italic;text-transform:none;">After Company&#x2019;s 2017 Annual Meeting</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="text-transform:uppercase;display:inline;font-family:Calibri;font-weight:bold;">ROCKVILLE, MD, March 13</font><font style="text-transform:uppercase;display:inline;font-family:Calibri;font-weight:bold;text-transform:none;">, 2017&nbsp;</font><font style="text-transform:uppercase;display:inline;font-family:Calibri;">&#x2013; &nbsp;</font><font style="display:inline;font-family:Calibri;">GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Scott Koenig, M.D., Ph.D., to its Board of Directors. Dr. Koenig is President and Chief Executive Officer and a member of the Board of Directors of MacroGenics (NASDAQ: MGNX), a company specializing in antibody-based therapies for cancers and other diseases. He also serves as Chairman of the Board of the Applied Genetic Technologies Corporation&nbsp;(NASDAQ: AGTC).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">&#x201C;We are delighted to have someone with the breadth and depth of Dr. Koenig&#x2019;s scientific and business expertise join our Board of Directors as we move our portfolio of product candidates&nbsp;into later stages of clinical development and closer to commercialization,&#x201D; said&nbsp;</font><font style="display:inline;font-family:Calibri;text-decoration:underline;">Rachel King</font><font style="display:inline;font-family:Calibri;">, CEO of GlycoMimetics. &#x201C;His more than 30 years of accomplishment and leadership in research and biotechnology, and his specific work at the helm of a company dedicated to cancer therapeutics, will be true assets to the GlycoMimetics team.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">Dr. Koenig has been President, CEO and a director of MacroGenics since 2001 and was one of the company&#x2019;s founders. Previously, he was Senior Vice President of Research at MedImmune,&nbsp;participating in the selection and maturation of the company&#x2019;s product pipeline. Before that, he worked in the National Institute of Allergy and Infectious Diseases&#x2019; Laboratory of Immunoregulation. &nbsp;In addition to serving as Chair of the Applied Genetic Technologies Corporation, he also serves as a member of the Board of Directors of the Biotechnology </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">Innovation Organization (BIO) and the International Biomedical Research Alliance, and co-chairs the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research (IBBR) at the University of Maryland.&nbsp;Previously, he served as a member of the Scientific Management Review Board at the NIH, and of the Board of Directors of Children&#x2019;s National Health System, where he was also the Chairman of the Board of the Children&#x2019;s Research Institute.&nbsp; He received his M.D. from the University of Texas Health Science Center in Houston, and his Ph.D. and A.B. from Cornell University. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">&#x201C;I&#x2019;m honored to serve on the Board of Directors of GlycoMimetics, and to help guide their efforts to advance their promising drug candidates,&#x201D; said Dr. Koenig. &#x201C;I&#x2019;ve observed many biotechnology companies as they have worked through the drug development and approval process, and am particularly impressed with the potential of GlycoMimetics and its product candidate portfolio.&nbsp;We share a dedication to making a meaningful difference for those facing unmet medical needs.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">In addition to the appointment of Dr. Koenig, GlycoMimetics also announced that two of its long-standing Board members would be stepping down. Franklin Top, Jr., M.D., will not be running for re-election when his term expires after the Company&#x2019;s upcoming Annual Meeting. John J. Baldwin, Ph.D., has also&nbsp;notified the Board of his intention to resign, effective after the GlycoMimetics Annual Meeting.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">&#x201C;I am so grateful for the insights and contributions that Drs. Top and Baldwin have provided to the GlycoMimetics team over the years they have served on our Board of Directors,&#x201D; said Mrs. King. &#x201C;They have&nbsp;each played a critical role in the success of GlycoMimetics, &nbsp;and they will be sincerely missed.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;">About GlycoMimetics, Inc. </font>
		</p>
		<p style="margin:0pt -4.5pt 12pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">GlycoMimetics&nbsp;is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt -4.5pt 12pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial in multiple myeloma.&nbsp;GlycoMimetics&nbsp;has also recently initiated a clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin&nbsp;antagonist.&nbsp;GlycoMimetics&nbsp;is located in&nbsp;Rockville, MD&nbsp;in the&nbsp;BioHealth Capital Region. Learn more at&nbsp;</font><font style="display:inline;font-family:Calibri;text-decoration:underline;">www.glycomimetics.com</font><font style="display:inline;font-family:Calibri;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;">Forward-Looking Statements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">This press release contains forward-looking statements regarding GlycoMimetics&#x2019; planned activities with respect to the clinical development of its drug candidates, &nbsp;GMI-1271 and GMI-1359.&nbsp; Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the availability and timing of data from ongoing clinical trials, the uncertainties inherent in the initiation of future clinical trials, whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials, expectations for regulatory approvals, availability of funding sufficient for GlycoMimetics&#x2019; foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that could affect the availability or commercial potential of GlycoMimetics&#x2019; drug candidates and other factors discussed in the &#x201C;Risk Factors&#x201D; section of GlycoMimetics&#x2019; Annual Report on Form 10-K that was filed with the U.S. Securities and Exchange Commission on February 29, 2016, and other filings GlycoMimetics makes with the Securities and Exchange Commission from time to time. In addition, the forward-looking statements included in this press release represent GlycoMimetics&#x2019; views as of the date hereof. GlycoMimetics anticipates that subsequent events and developments may cause its views to change. However, while GlycoMimetics may elect to update these forward-looking statements at some point in the future, GlycoMimetics specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing GlycoMimetics&#x2019; views as of any date subsequent to the date hereof.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;"># # #</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">Source: GlycoMimetics</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;">Investor Contact:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">Shari Annes</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">Phone: 650-888-0902</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">Email: sannes@annesassociates.com</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;">Media Contact:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">Jamie Lacey-Moreira</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">Phone: 410-299-3310</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">Email: jamielacey@presscommpr.com</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>glycex991001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glycex991001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !     %$2
M  0    !             8:@  "QC__; $, " 8&!P8%" <'!PD)" H,% T,
M"PL,&1(3#Q0=&A\>'1H<'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T
M,O_; $,!"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_  !$( $X!:0,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M)Y_B'P'?6UF.7N+6<3;!ZD 8'XD5V^@>(M+\3Z8NH:3=+/ 3ANS(W]UAU!H
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M$/AVQUBWP(KJ$2$9^X>C*3[$$?A7$_!4!O!5Z" 0=3G!!^BUQVI:E?\ @?\
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MEM>?&LGLS_\ H-'B_P#UUK_NM_2G%1YXPY5JA2<^253F>C([F\U];<:@S>5
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M9(E\L,3][! !;OPH'H37H7A#X8Z!X1"3Q0_;-1')O+@ L#_LCHOX<^]=I10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
